Your session is about to expire
← Back to Search
Recombinant EphB4-HSA Fusion Protein for Head and Neck Squamous Cell Carcinoma
Study Summary
This trial is testing the side effects and best dose of a new protein drug when given with standard chemotherapy drugs to treat patients with solid tumors that have spread and can't be cured or controlled with treatment.
- Head and Neck Squamous Cell Carcinoma
- Pancreatic Cancer
- Gallbladder Cancer
- Non-Small Cell Lung Cancer
- Cholangiocarcinoma
- Pancreatic Adenocarcinoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What medical conditions commonly call for the treatment of Recombinant EphB4-HSA Fusion Protein?
"Recombinant EphB4-HSA Fusion Protein is prescribed to patients that have had prior adjuvant anthracycline therapy, and can be used to alleviate symptoms related to head maladies, hypoalbuminemia and neoplasm metastasis."
Are there any vacancies on this clinical trial?
"At this point in time, no additional candidates are being accepted for the study posted on September 3rd 2015. However, if you're keen to explore other trials; 6219 studies recruiting participants with oral squamous cell carcinoma and 1752 clinical trials involving Recombinant EphB4-HSA Fusion Protein are actively accepting patients."
Has the FDA authorized Recombinant EphB4-HSA Fusion Protein for widespread use?
"Due to its limited safety and efficacy data, Recombinant EphB4-HSA Fusion Protein received a score of 1 on the Power scale."
How many participants have been enrolled to this trial thus far?
"Unfortunately, the trial is not presently accepting new patients. First posted on September 3rd 2015 and recently updated August 5th 2022, no more participants can be enrolled in this particular study at present. For those searching for other trials related to oral squamous cell carcinoma there are 6219 active studies while 1752 are recruiting patients for Recombinant EphB4-HSA Fusion Protein treatments."
Share this study with friends
Copy Link
Messenger